Deep Intelligent Pharma

Deep Intelligent Pharma (DIP) develops an AI-powered platform that integrates large-scale AI models with scientific computing to compress the drug development cycle from molecular screening to candidate confirmation. Its flagship AI CRO 6.0 platform deploys tens of thousands of AI agents working 24/7 to accelerate protocol design (12x), clinical operations monitoring (50x), medical writing (15x), and data management (10x). The company also offers a Molecule Design Engine for precision drug discovery and an Agent Matrix for multi-agent orchestration. DIP serves both life sciences and material science, covering agrochemicals, batteries, semiconductors, and alloys. With over 1,500 cumulative clients including Roche, GSK, and Bayer, DIP holds approximately 16% of the AI-driven clinical CRO market share per Frost & Sullivan. Founded in 2017 and headquartered in Beijing, China, the company has raised approximately $125 million at the Series E stage, with investors including HSG (HongShan), CDH Investments, CITIC Capital, and ZhenFund.